The probiotic CFU count on packaging has been climbing for years. Ten billion, fifty billion, a hundred billion.
The honest answer to whether that helps isn’t a flat no. It’s that dose-response exists for some outcomes and not for others — and the packaging number rarely tells you which one you’re buying.
The answer splits by outcome
A review of dose-response relationships in human probiotic studies found the picture divides cleanly[1].
| Outcome | Dose-response? |
| Antibiotic-associated diarrhoea | Yes |
| Blood pressure | Yes — doses above 10¹¹ CFU more effective |
| Faecal recovery of the strain | Yes |
| *C. difficile*-associated diarrhoea | No |
| Necrotising enterocolitis | No |
| Prevention of atopic dermatitis | No |
| Slow intestinal transit | No |
| Irritable bowel syndrome relief | No |
| Colorectal cancer prophylaxis | No |
[Table 1] Where dose-response was and wasn’t found · Source: Review of Human Study Capacity-Response[1][4]
Two positives and seven negatives, from the same review.
So “more is better” isn’t a myth in the sense of being wrong everywhere. It’s a claim that happens to be true for a minority of studied outcomes and gets applied to all of them.
Two more findings in the same direction
A 2025 dose-response meta-analysis examined probiotics and brain-derived neurotrophic factor, using trials spanning 10⁸ to 10¹¹ CFU per day. It found a significant effect on BDNF overall — but stated that the lack of a dose-response relationship with CFU/day suggests that simply increasing the dosage may not enhance efficacy[2].
What did matter in that analysis was duration, with a notable non-linear effect after ten weeks[2].
And in critical care, a systematic review defined high dose as more than 5 × 10⁹ CFU per day and low dose as less. It found no significant difference in infectious complications between the groups[3].
Time and strain, in these analyses, carried more weight than count.
Why the relationship flattens
The mechanism proposed is that the bottleneck moves.
Beyond a certain threshold, additional CFU stop translating into additional benefit, because the limiting factors shift from bacterial quantity to survival, adherence, and metabolic activity in the host environment[5].
The journey explains it. Bacteria pass through gastric acid at pH 1.5 to 3.5, then bile salts in the small intestine — both hostile to survival[5]. Whatever arrives then has to adhere to the intestinal lining and do something metabolically useful.
Adding more bacteria at the top of that funnel doesn’t widen the funnel. Past the point where survival rather than quantity is limiting, the extra organisms have nowhere to go.
The number on the label isn’t the number delivered
A separate issue, and one that undermines cross-product comparison entirely.
CFU counts may be stated at time of manufacture or at expiry[5]. Those are different numbers describing the same product, and the gap between them depends on storage.
Temperature fluctuation, humidity and oxygen exposure all degrade viability[5]. Which produces this consequence:
A product starting at 50 billion CFU but stored improperly may deliver fewer live organisms than one starting at 10 billion with protective encapsulation and refrigeration[5].
So comparing two headline numbers assumes both were measured the same way and both were handled the same way. Neither assumption is safe.
As covered in the strain naming post, the CFU figure is one variable alongside strain designation, delivery technology, and the host’s own baseline microbiome[5].
What the right question is
The International Probiotics Association states the useful rule directly:
The dose or CFU count should match the CFU level shown in an efficacy study to endow a benefit. One size certainly doesn’t fit all, making a broad recommendation of what is adequate virtually impossible[4].
That reframes the whole question. The target isn’t *high*. The target is *whatever the trial used* for that strain and that outcome.
Dose-response also appears to be strain-specific. Meta-analyses found a break-point for effectiveness of Lactobacillus rhamnosus GG in treating acute gastroenteritis in children, while no dose-response was observed for two other probiotics assessed in the same review[1].
Which means even the outcomes where more helps don’t generalise across strains.
If you’re in Korea
The regulatory framework here draws the line explicitly, as covered in an earlier post.
Korea’s notified probiotic standard specifies a daily intake of 100 million to 10 billion CFU. That’s a range with an upper bound, not a minimum to exceed.
A product advertising 100 billion CFU is presenting a figure well above what the recognised functional claim was based on. That doesn’t make the product defective — but the advertising is emphasising something the approval framework doesn’t ask for.
The approved wording covers proliferation of beneficial bacteria, suppression of harmful bacteria, and bowel regularity. Nothing in that wording scales with the headline number.
Practical reading
Check the reference point. Manufacture or expiry? Expiry-stated counts are more informative.
Check storage requirements, and whether the product has been stored that way in transit and at home.
Look for the strain designation, not just the genus and species — the last part of the name is what connects a product to a trial.
Treat a very large number as a marketing decision rather than a quality signal, unless it matches a specific studied protocol.
Remember what an earlier post found: in Korean consumer testing, products listing many strains often had most of those strains present in negligible quantities. Big numbers on packaging can describe several different things.
Closing
I’d have written this as a straightforward debunk. The evidence doesn’t support that.
Dose-response is real for antibiotic-associated diarrhoea, for blood pressure above 10¹¹ CFU, and for how much of a strain shows up in stool. For seven other outcomes in the same review, it wasn’t found. And for one strain there’s a break-point where two others showed nothing.
So the claim isn’t false. It’s unqualified — applied everywhere when it was demonstrated in a few places.
The replacement isn’t “less is better” either. It’s that the number should match a study, and a number chosen to look impressive on a shelf hasn’t been matched to anything.
At a Glance
- Dose-response was found for antibiotic-associated diarrhoea, blood pressure (above 10¹¹ CFU) and faecal recovery
- It was not found for *C. difficile* diarrhoea, necrotising enterocolitis, atopic dermatitis, slow transit, IBS or colorectal cancer prophylaxis
- A 2025 BDNF meta-analysis across 10⁸–10¹¹ CFU/day found no dose-response — duration mattered more
- In critical care, high versus low dose showed no significant difference in infectious complications
- Past a threshold the limiting factor becomes survival, adherence and metabolic activity, not quantity
- CFU may be stated at manufacture or at expiry — and poor storage can leave a 50 billion product delivering less than a 10 billion one
- The dose should match the CFU level used in an efficacy study for that strain and outcome
- Korea’s notified standard specifies a range of 100 million to 10 billion CFU per day, with an upper bound
※ This article is for general information and does not replace medical advice. It does not evaluate any specific product. Recognised ingredient standards are revised periodically — confirm current details on official sources. If you take immunosuppressive medication or have a serious illness, consult a clinician before taking probiotics, and stop and seek advice if adverse symptoms occur.
References
- “A review of dose-responses of probiotics in human studies”, Beneficial Microbes 2017;8(2), https://dx.doi.org/10.3920/BM2016.0140
- “Impact of probiotic supplementation on serum levels of brain-derived neurotrophic factor: GRADE-based dose-response meta-analysis”, BMC Nutrition 2025, https://link.springer.com/article/10.1186/s40795-025-01152-9
- “Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review”, ScienceDirect, https://www.sciencedirect.com/science/article/pii/S0924857926000038
- “Probiotic Supplements: What is an Adequate Dosage?”, International Probiotics Association, https://ipa-biotics.org/probiotic-dosage-what-is-adequate/
- “Does a higher CFU count mean a better probiotic?” (non-linear dose-response, survival bottleneck, labelling reference point), Superpower, https://superpower.com/guides/probiotics-cfu